Media Thread, page-14265

"The trial timelines they forecast were grossly extended, stalled, and shelved."
IMU are focus on the 3 IP with FDA IND which is understandable as BP will more than likely purchase and offer more for IP with FDA IND.

"The results they managed to get out were underwhelming."
The last clinical trial update for VAXINIA showed excellent result for so early in Ph1 clinical trial and the previous clinical trial update for HER-Vaxx was very good so what underwhelming results are you talking about????

"The salaries and staffing went through the roof."
The excess expenditure cost was for the manufacture plant needed for the Azer-Cel acquisition which added $2M more per quarter to the expenditure and has since been sold and 2/3 of IMU's expenditure has always been on R&D.

"The dilution tripled without regard or care."
The ATH was $3.5B when the pps was at 60c so the O/S was 6B and is now 7.3B so how has the dilution tripled????